Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06121297 · ClinicalTrials.gov registry record · Phase 1
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
A Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis, sponsored by Cabaletta Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 20
- Study locations
NCT06121297 is a Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis that is actively recruiting participants, run by Cabaletta Bio. The registered enrollment target is 28 participants, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06121297, a Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis, is actively recruiting participants, sponsored by Cabaletta Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 20
- Study locations
Study Summary
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Conditions Studied
Interventions
- BIOLOGICAL CABA-201
Study Locations (20)
Massachusetts
- Tufts Medical Center - Boston
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
- Brigham and Women's Hospital - Boston
- UMass Memorial Hospital - Worcester
California
- University of California Irvine - Orange
- UC Davis Health - Sacramento
Florida
- University of Florida Health - Gainesville
- Mayo Clinic - Jacksonville
Illinois
- Northwestern Memorial Hospital - Chicago
- The University of Chicago Medical Center - Chicago
New York
- Columbia University Irving Medical Center - New York
- University of Rochester - Rochester
Connecticut
- Yale University - New Haven
Georgia
- Emory University - Atlanta
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-02-16 |
| Est. Completion | 2029-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06121297
The ClinicalTrials.gov registry entry for NCT06121297 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (93% lower). The listed sponsor is Cabaletta Bio, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which CABA-201 is the first listed.
NCT06121297 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Massachusetts, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06121297 about?
NCT06121297 is a clinical study titled "RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus". RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
What is the current status of trial NCT06121297?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2024-02-16. Estimated completion is 2029-12.
What conditions does trial NCT06121297 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus, Lupus Nephritis.
What interventions are being tested in trial NCT06121297?
The interventions under investigation include: CABA-201 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06121297?
This trial is sponsored by Cabaletta Bio, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06121297 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
REACT-01: Reversing Autoimmunity Through Cell Therapy
RECRUITING · Phase 1
-
Alnuctamab for Refractory SLE (LATTE Study)
RECRUITING · Phase 1
-
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.